{"id":55117,"date":"2023-03-23T07:03:18","date_gmt":"2023-03-23T06:03:18","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/innate-pharma-reports-full-year-20221-financial-results-and-business-update\/"},"modified":"2023-03-23T07:03:18","modified_gmt":"2023-03-23T06:03:18","slug":"innate-pharma-reports-full-year-20221-financial-results-and-business-update","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/innate-pharma-reports-full-year-20221-financial-results-and-business-update\/","title":{"rendered":"Innate Pharma Reports Full Year 2022(1) Financial Results and Business Update"},"content":{"rendered":"<div>\n<ul class=\"bwlistdisc\">\n<li>\n<b><i>Sanofi collaboration for Natural Killer cell engager therapeutics expanded to B7-H3 ANKET<\/i><\/b><sup>\u00ae <\/sup><b><i>program and two additional targets, with \u20ac25 million payment<\/i><\/b>\n<\/li>\n<li>\n<b><i>Encouraging preliminary TELLOMAK Phase 2 efficacy data for lacutamab in advanced cutaneous T cell lymphoma in S<\/i>\u00e9<i>zary syndrome and mycosis fungoides<\/i><\/b>\n<\/li>\n<li>\n<b><i>First patient dosed in monalizumab PACIFIC-9 Phase 3 lung cancer clinical trial with $50M payment from AstraZeneca<\/i><\/b>\n<\/li>\n<li>\n<b><i>Cash position of \u20ac136.6 million<sup>2<\/sup> as of December 31, 2022 (not including the \u20ac25 million payment from Sanofi), anticipated cash runway into mid 2025<\/i><\/b>\n<\/li>\n<li>\n<b><i>Conference call to be held today at 2:00 p.m. CET \/ 9:00 a.m. EDT<\/i><\/b>\n<\/li>\n<\/ul>\n<p>MARSEILLE, France&#8211;(BUSINESS WIRE)&#8211;<a href=\"https:\/\/twitter.com\/hashtag\/ANKET?src=hash\" target=\"_blank\" rel=\"noopener\">#ANKET<\/a>&#8211;Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (\u201c<b>Innate<\/b>\u201d or the \u201c<b>Company<\/b>\u201d) today reported its consolidated financial results<sup>1<\/sup> for the year ending December 31, 2022. The consolidated financial statements are attached to this press release.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20230322005782\/en\/1245155\/4\/INNATEvertnoirDS.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230322005782\/en\/1245155\/21\/INNATEvertnoirDS.jpg\"><\/a><\/p>\n<p>\n<i>\u201cIn 2022 we made important progress in our pipeline, both on our clinical and preclinical projects as well as maintaining a strong financial position. We\u2019re continuing to see encouraging efficacy signals for our proprietary program lacutamab in advanced cutaneous T cell lymphomas. In the meantime, our innovative R&amp;D pipeline progression was marked by the expansion of our partnership with Sanofi to develop new NK Cell Engager Therapeutics from our ANKET<\/i><sup>\u00ae<\/sup><i> platform, including solid tumors. The Sanofi collaboration is an example of how we use partnerships to build value at Innate, also underlined by our partnership with AstraZeneca for monalizumab which is in a Phase 3 trial for non-small cell lung cancer,\u201d <b>said Mondher Mahjoubi, Chief Executive Officer of Innate Pharma<\/b>. \u201cAs we look to progress our pipeline in house or with partnerships, we look forward to new milestones in 2023 with important inflection points, including final readouts from the TELLOMAK Phase 2 trial with lacutamab and further updates for our ANKET<\/i><sup>\u00ae<\/sup><i> assets.\u201d<\/i>\n<\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignc\">\n<tr>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwleftsingle bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n\u00a0\n<\/p>\n<p class=\"bwalignc bwcellpmargin\">\n<b><i>Webcast and conference call will be held today at 2:00pm CET (9:00am EDT)<\/i><\/b>\n<\/p>\n<p class=\"bwalignc bwcellpmargin\">\n<i>Access to live webcast:<\/i>\n<\/p>\n<p class=\"bwalignc bwcellpmargin\">\n<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fevents.q4inc.com%2Fattendee%2F611394672&amp;esheet=53366651&amp;newsitemid=20230322005782&amp;lan=en-US&amp;anchor=https%3A%2F%2Fevents.q4inc.com%2Fattendee%2F611394672&amp;index=1&amp;md5=4e2281bee50969f00ece9049d25c464a\" rel=\"nofollow noopener\" shape=\"rect\">https:\/\/events.q4inc.com\/attendee\/611394672<\/a>\n<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<p class=\"bwalignc bwcellpmargin\">\n<i>Participants may also join via telephone using the registration link below:<\/i>\n<\/p>\n<p class=\"bwalignc bwcellpmargin\">\n<i><a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fregistrations.events%2Fdirect%2FQ4E60253&amp;esheet=53366651&amp;newsitemid=20230322005782&amp;lan=en-US&amp;anchor=https%3A%2F%2Fregistrations.events%2Fdirect%2FQ4E60253&amp;index=2&amp;md5=b128b587c12d71e3701930392e559daa\" rel=\"nofollow noopener\" shape=\"rect\">https:\/\/registrations.events\/direct\/Q4E60253<\/a><\/i>\n<\/p>\n<p class=\"bwalignc bwcellpmargin\">\n\u00a0\n<\/p>\n<p class=\"bwalignc bwcellpmargin\">\n<i>This information can also be found on the Investors section of the Innate Pharma website, <\/i><i><a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.innate-pharma.com&amp;esheet=53366651&amp;newsitemid=20230322005782&amp;lan=en-US&amp;anchor=www.innate-pharma.com&amp;index=3&amp;md5=de3a7b45ed6501b23a7d56b5d6e1e9f7\" rel=\"nofollow noopener\" shape=\"rect\">www.innate-pharma.com<\/a><\/i><i>.<\/i>\n<\/p>\n<p class=\"bwalignc bwcellpmargin\">\n<i>A replay of the webcast will be available on the Company website for 90 days following the event.<\/i>\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl\">\n<tr>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<sup>1<\/sup> This press release contains financial data approved by the Executive Board based on our consolidated financial statements for the year ended December 31, 2022. The audit is in progress at the date of this communication.\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<sup>2<\/sup> Including short term investments (\u20ac17.3m) and non-current financial instruments (\u20ac35.1m).\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<div class=\"bwpagebreakafter\">\n<\/div>\n<p>\n<b>Pipeline highlights:<\/b>\n<\/p>\n<p>\n<b><span class=\"bwuline\">Lacutamab (IPH4102, anti-KIR3DL2 antibody):<\/span><\/b>\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nInnate continues to see progress for lacutamab with final data from the TELLOMAK Phase 2 trial for both mycosis fungoides and S\u00e9zary syndrome expected in H2 2023.<\/p>\n<ul class=\"bwlistcircle\">\n<li>\nIn preliminary results confirming clinical activity and a favorable safety profile in patients with mycosis fungoides (MF) who were previously treated with at least two lines of systemic therapy, lacutamab produced a global objective response rate (ORR) of 28.6% (95% confidence interval [CI]: 13.8-50.0) in the KIR3DL2-expressing MF patients (n=21), including 2 complete responses and 4 partial responses (<b>EORTC-CLTG (European Organisation for Research and Treatment of Cancer &#8211; Cutaneous Lymphoma Tumours Group) 2022 meeting &#8211; September 2022<\/b>).\n<\/li>\n<li>\nIn a preliminary analysis, lacutamab demonstrated clinical activity and a favorable safety profile in heavily pretreated, post-mogamulizumab patients with advanced S\u00e9zary syndrome. In the Intention To Treat (ITT) population (n=37), the global ORR was 21.6% (8\/37). ORR in the blood was 37.8% (95% CI: 24.1-53.9), with 21.6% (8\/37) achieving complete response (CR). ORR in the skin was 35.1% (95% CI: 21.8-51.2). In the Evaluable for Efficacy (EES) population (n=35), global objective response rate (ORR) was 22.9% (8\/35). ORR in the blood was 40.0% (95% CI: 25.6-56.4) and ORR in the skin was 37.1% (95% CI: 23.2 53.7) (<b>2022 ASH (American Society Hematology) Annual Meeting &#8211; December 2022<\/b>).\n<\/li>\n<\/ul>\n<\/li>\n<li>\nTwo parallel clinical trials to study lacutamab in patients with KIR3DL2-expressing, relapsed\/refractory peripheral T-cell lymphoma (PTCL) are ongoing. Initial PTCL data are expected in H2 2023.<\/p>\n<ul class=\"bwlistcircle\">\n<li>\n<b>Phase 1b trial:<\/b> a Company-sponsored Phase 1b clinical trial to evaluate lacutamab as a monotherapy in patients with KIR3DL2-expressing relapsed PTCL. A poster on the trial design was presented at the ESMO (European Society for Medical Oncology) 2022 conference.\n<\/li>\n<li>\n<b>Phase 2 KILT (anti-KIR in T Cell Lymphoma) trial:<\/b> The Lymphoma Study Association (LYSA) initiated an investigator-sponsored, randomized trial to evaluate lacutamab in combination with chemotherapy GEMOX (gemcitabine in combination with oxaliplatin) versus GEMOX alone in patients with KIR3DL2-expressing relapsed\/refractory PTCL.\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p>\n<b><span class=\"bwuline\">ANKET<\/span><sup>\u00ae<\/sup> <span class=\"bwuline\">(Antibody-based NK cell Engager Therapeutics):<\/span><\/b>\n<\/p>\n<p>\nANKET<sup>\u00ae<\/sup> is Innate\u2019s proprietary platform for developing next-generation, multi-specific NK cell engagers to treat certain types of cancer. Innate\u2019s pipeline includes four public drug candidates born from the ANKET<sup>\u00ae<\/sup> platform: IPH6101 (CD123-targeted), IPH6401 (BCMA-targeted), IPH62 (B7-H3-targeted) and tetra-specific IPH6501 (CD20-targeted). Several other undisclosed proprietary preclinical targets are being explored.\n<\/p>\n<div class=\"bwpagebreakafter\">\n<\/div>\n<p>\n<b>IPH6101, IPH6401 and IPH62 (partnered with Sanofi)<\/b>\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nThe Phase 1\/2 clinical trial by Sanofi is progressing well, evaluating IPH6101\/SAR\u2019579, the first NKp46\/CD16-based CD123-targeted ANKET<sup>\u00ae <\/sup>platform NK cell engager, in patients with relapsed or refractory acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia or high-risk myelodysplastic syndrome.<\/p>\n<ul class=\"bwlistcircle\">\n<li>\nPreclinical data showing the control of AML cells by a trifunctional NKp46-CD16a-NK cell engager targeting CD123 were published in <i>Nature Biotechnology<\/i> in January 2023.\n<\/li>\n<\/ul>\n<\/li>\n<li>\nOn July 21, 2022, the Company announced that its partner Sanofi had made the decision to progress IPH6401\/SAR\u2019514, a BCMA-targeting NK cell engager into investigational new drug (IND)-enabling studies. Selection of IPH6401\/SAR\u2019514 triggered a \u20ac3M milestone payment to Innate.\n<\/li>\n<li>\nAs announced on December 19, 2022, Sanofi licensed IPH62, a NK cell engager program targeting B7-H3 from Innate\u2019s ANKET<sup>\u00ae<\/sup> platform. Sanofi also have the option to add up to two additional ANKET<sup>\u00ae<\/sup> targets. Upon candidate selection, Sanofi will be responsible for all development, manufacturing and commercialization. Under the terms of the agreement, Innate received a \u20ac25m upfront payment and is eligible for up to \u20ac1.35bn total in preclinical, clinical, regulatory and commercial milestones plus royalties on potential net sales.\n<\/li>\n<\/ul>\n<p>\n<b>IPH6501 (proprietary)<\/b>\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nProgress continues toward a Phase 1 clinical trial in 2023 for the proprietary CD20 targeted tetra-specific ANKET<sup>\u00ae<\/sup>, IPH6501.<\/p>\n<ul class=\"bwlistcircle\">\n<li>\nAn October 2022 edition of <i>Cell Reports Medicine<\/i> described the development of Innate\u2019s fit-for-purpose ANKET<sup>\u00ae<\/sup> antibody-based tetra-specific molecule to harness the antitumor functions of NK cells, boosting their capacity to proliferate, to accumulate at the tumor site and to kill tumor cells.\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p>\n<b><span class=\"bwuline\">Monalizumab (anti-NKG2A antibody), partnered with AstraZeneca:<\/span><\/b>\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nInnate continues to see progress for monalizumab in the early non-small cell lung cancer (NSCLC) setting, with the ongoing Phase 3 PACIFIC-9 study run by AstraZeneca. The study is evaluating durvalumab (anti-PD-L1) in combination with monalizumab or AstraZeneca\u2019s oleclumab (anti-CD73) in patients with unresectable, Stage III NSCLC who have not progressed following definitive platinum-based concurrent chemoradiation therapy (CRT).<\/p>\n<ul class=\"bwlistcircle\">\n<li>\nOn April 29, 2022, Innate announced a $50 million milestone payment from AstraZeneca was triggered for dosing the first patient in the PACIFIC-9 Phase 3 clinical trial.\n<\/li>\n<\/ul>\n<\/li>\n<li>\nDetailed results from the randomized AstraZeneca-sponsored Phase 2 COAST clinical trial, including monalizumab data in combination with durvalumab, were published in the <i>Journal of Clinical Oncology<\/i> in April 2022. The results were initially presented during the European Society for Medical Oncology (ESMO) Congress 2021. The results of the interim analysis showed monalizumab in combination with durvalumab reduced the risk of disease progression by 58% (improved progression-free survival (PFS) with a hazard ratio of 0.42) and improved objective response rate (ORR) compared to durvalumab alone in patients with unresectable, Stage III NSCLC who had not progressed after concurrent CRT. The Journal of Clinical Oncology publication includes exploratory subgroup analysis.\n<\/li>\n<li>\nPartner AstraZeneca presented data from Phase 2 NeoCOAST randomized trial in resectable, early-stage NSCLC at the 2022 American Association for Cancer Research (AACR) Annual Meeting and ESMO 2022 congress. The presentations highlighted improved disease responses with durvalumab in combination with monalizumab, oleclumab or danvatirsen, when compared to durvalumab alone. The follow-up randomized Phase 2 clinical trial, NeoCOAST-2, is enrolling patients with resectable, stage IIA-IIIB NSCLC to receive neoadjuvant durvalumab combined with chemotherapy and either oleclumab or monalizumab, followed by surgery and adjuvant durvalumab plus oleclumab or monalizumab.\n<\/li>\n<li>\nOn August 1, 2022, Innate announced that a planned futility interim analysis of the Phase 3 INTERLINK-1 study sponsored by AstraZeneca did not meet a pre-defined threshold for efficacy. The Company announced that, based on the result and the recommendation of an Independent Data Monitoring Committee, the study was to be discontinued. There were no new safety findings. AstraZeneca plan to share the data in due course. The INTERLINK-1 study evaluated monalizumab in combination with cetuximab vs. cetuximab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck who have been previously treated with platinum-based chemotherapy and PD-(L)1 inhibitors.\n<\/li>\n<\/ul>\n<div class=\"bwpagebreakafter\">\n<\/div>\n<p>\n<b><span class=\"bwuline\">IPH5201 (anti-CD39), partnered with AstraZeneca:<\/span><\/b>\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nThe MATISSE Phase 2 clinical trial conducted by Innate in neoadjuvant lung cancer for IPH5201, an anti-CD39 blocking monoclonal antibody developed in collaboration with AstraZeneca, has started and is awaiting first patient dosed.<\/p>\n<ul class=\"bwlistcircle\">\n<li>\nIn August 2022 Innate received a $5 million milestone payment from AstraZeneca and will be responsible for conducting the study. AstraZeneca and Innate will share study costs and AstraZeneca will supply clinical trial drugs.\n<\/li>\n<li>\nPreclinical data supporting the rationale for the Phase 2 development in NSCLC were presented at the 2022 ESMO Immuno-Oncology (IO) Annual Congress in December.\n<\/li>\n<li>\nAstraZeneca conducted a Phase 1 trial in solid tumors with IPH5201 alone or in combination with durvalumab and presented a poster entitled \u201cIPH5201 as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumours\u201d at the 2022 ESMO IO Annual Congress in December.\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p>\n<b><span class=\"bwuline\">IPH5301 (anti-CD73):<\/span><\/b>\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nThe investigator-sponsored CHANCES Phase 1 trial of IPH5301, in collaboration with Institut Paoli-Calmettes is ongoing. The trial will be conducted in two parts, Part 1, the dose escalation, followed by a Part 2 safety expansion study cohort. Part 2 will evaluate IPH5301 in combination with chemotherapy and trastuzumab in HER2+ cancer patients. The design of the Phase 1 study was highlighted at the 2022 ESMO IO congress in December.\n<\/li>\n<\/ul>\n<p>\n<b><span class=\"bwuline\">Avdoralimab (anti-C5aR1):<\/span><\/b>\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nThe Company has decided to discontinue the development of avdoralimab in bullous pemphigoid. The Company will continue to evaluate out-licensing as a potential next step.\n<\/li>\n<\/ul>\n<div class=\"bwpagebreakafter\">\n<\/div>\n<p>\n<b><span class=\"bwuline\">Preclinical assets:<\/span><\/b>\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nFueling the R&amp;D engine, the Company continues to develop different approaches for the treatment of cancer utilizing its antibody engineering capabilities to deliver novel assets, with its innovative ANKET<sup>\u00ae<\/sup> platform and continuing to explore Antibody Drug Conjugates (ADC) formats.\n<\/li>\n<li>\nDuring the period, the Company received from AstraZeneca a notice that it will not exercise its option to license the four preclinical programs covered in the &#8220;Future Programs Option Agreement&#8221;. This option agreement was part 2018 multi-term agreement between AstraZeneca and Innate. Innate regained full rights to further develop the four preclinical molecules.\n<\/li>\n<\/ul>\n<p>\n<b>Corporate Update:<\/b>\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nOn May 3, 2022 Innate announced the commencement of an At-The-Market (ATM) program, pursuant to which it may, from time to time, offer and sell to eligible investors a total gross amount of up to $75 million American Depositary Shares (\u201cADS\u201d). Each ADS representing one ordinary share of Innate. As of December 31, 2022, the balance available under our May 2022 sales agreement remains at $75 million.\n<\/li>\n<li>\nDr Sally Bennett was appointed as new member of the Supervisory Board in May 2022. She was appointed as a member of the Audit Committee. On the same date it was announced that Mr Patrick Langlois decided to resign from his mandate of Supervisory Board member of Innate Pharma.\n<\/li>\n<li>\nIn January 2023, Mrs Claire de Saint Blanquat, Vice President Legal and Corporate Affairs, and Mr Henry Wheeler, Vice President Investor Relations and Communications, were appointed to the Leadership Team.\n<\/li>\n<\/ul>\n<div class=\"bwpagebreakafter\">\n<\/div>\n<p>\n<b>Financial highlights for 2022:<\/b>\n<\/p>\n<p>\nThe key elements of Innate\u2019s financial position and financial results as of and for the year ended December 31, 2022 are as follows:\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nCash, cash equivalents, short-term investments and financial assets amounting to \u20ac136.6 million (\u20acm) as of December 31, 2022 (\u20ac159.7m as of December 31, 2021), including financial instruments amounting to \u20ac35.1m (\u20ac39.9m as of December 31, 2021). Cash, cash equivalents as of December 31, 2022 do not include the \u20ac25.0 million payment received from Sanofi in March 2023.\n<\/li>\n<li>\nAs of December 31, 2022, financial liabilities amount to \u20ac42.3m (\u20ac44.3m as of December 31, 2021). In August 2022, the Company obtained an extension for a period of five year (starting in 2022) with a one-year grace period (2023) of its State-Guaranted Loans (Pr\u00eats Garantis par l\u2019Etat \u201cPGE\u201d) from Soci\u00e9t\u00e9 G\u00e9n\u00e9rale (\u20ac20.0m) and BNP Paribas (\u20ac8.7m).\n<\/li>\n<li>\nRevenue and other income from continuing operations amounted to \u20ac57.7m in 2022 (2021: \u20ac24.7m). It mainly comprises revenue from collaboration and licensing agreements (\u20ac49.6m in 2022 vs \u20ac12.1m in 2021), and research tax credit (\u20ac7.9m in 2022 vs \u20ac10.3m in 2021, -23.1%):<\/p>\n<ul class=\"bwlistcircle\">\n<li>\nRevenue from collaboration and licensing agreements, which mainly resulted from the partial or entire recognition of the proceeds received pursuant to the agreements with AstraZeneca and Sanofi and which are recognized on the basis of the percentage of completion of the works performed by the Company under such agreements:<\/p>\n<ul class=\"bwlistsquare\">\n<li>\n(i) Revenue from collaboration and licensing agreements for monalizumab increased by \u20ac14.9m to \u20ac22.4m in 2022 (\u20ac7.5m in 2021). This change mainly results from the transaction price increase of \u20ac13.4m ($14.0m) triggered by the launch of the \u201cPACIFIC-9\u201d Phase 3 trial announced on April 29, 2022. This change in the transaction price generated a \u20ac12.6 million favorable cumulative adjustment in the revenue related to monalizumab agreements for the first half of 2022, partially offset by effects of the decrease in direct monalizumab research and development costs over the period as compared to the first half of 2021, in connection with the Phase 1 &amp; 2 trials maturity;\n<\/li>\n<li>\n(ii) Revenue related to IPH5201 for the year ended 2022 amounted to \u20ac4.7m and results from the entire recognition in revenue of the $5.0m milestone payment received in August 2022 from AstraZeneca following the signature on June 1, 2022 of an amendment to the initial contract signed in October 2018. This amendment sets the terms of the collaboration following AstraZeneca\u2019s decision to advance IPH5201 to a Phase 2 study;\n<\/li>\n<li>\n(iii) During 2022 first semester, the Company received from AstraZeneca a notice that it will not exercise its option to license the four preclinical programs covered in the &#8220;Future Programs Option Agreement&#8221;. This option agreement was part of the 2018 multi-term agreement between AstraZeneca and the Company under which the Company received an upfront payment of $20.0m (\u20ac17.4m). Innate has now regained full rights to further develop the four preclinical molecules. Consequently, the entire initial payment of $20.0m, or \u20ac17.4m was recognized as revenue in 2022.\n<\/li>\n<li>\n(iv) During 2022 first semester, the Company was informed of Sanofi&#8217;s decision to advance IPH6401\/SAR&#8217;514 into investigational new drug (IND)-enabling studies. As such, Sanofi has selected a second multispecific antibody engaging NK cells as a drug candidate. This selection triggered a \u20ac3.0m milestone payment from Sanofi. This amount was received by the Company on September 9, 2022.\n<\/li>\n<\/ul>\n<\/li>\n<li>\nThe variation in the research tax credit mainly results from a decrease in the amortization for the intangible assets related to acquired licenses (monalizumab and IPH5201) and to the decrease in personnel expenses allocated to research and development operations. In addition, there was a decrease in public subcontracting included in the calculation of the CIR. This decrease is the consequence of the end of the doubling of public subcontracting expenses eligible for the CIR since January 1, 2022, partly offset by an increase in private subcontracting expenses with accredited suppliers.\n<\/li>\n<\/ul>\n<\/li>\n<li>\nOperating expenses from continuing operations amounted to \u20ac74.1m in 2022 (2021: \u20ac72.5m, +2.2%):<\/p>\n<ul class=\"bwlistcircle\">\n<li>\nGeneral and administrative (G&amp;A) expenses from continuing activities amounted to \u20ac22.4m in 2022 (2021: \u20ac25.5m, -12.1%). This variation results cumulatively from (i) a decrease in wages mainly resulting from restructuring costs and higher annual bonuses level in 2021, (ii) a decrease in non-scientific advisory fees and (iii) a decrease in other general and administrative expenses.\n<\/li>\n<li>\nResearch and development (R&amp;D) expenses from continuing activities amounted to \u20ac51.7m in 2022 (2021: \u20ac47.0m, 9.9%). This variation mainly results from (i) an increase in direct research and development expenses (clinical and non-clinical) and (ii) an increase in other indirect research and development expenses, mainly linked to non-scientific and scientific fees.\n<\/li>\n<\/ul>\n<\/li>\n<li>\nThe avdoralimab intangible asset (anti-C5aR rights) total impairment of \u20ac41.0m (non-cash expense) following the Company\u2019s decision to stop avdoralimab development in bullous pemphigoid indication in inflammation.\n<\/li>\n<li>\nA net financial income of \u20ac0.5m in 2022 (2021: \u20ac2.3m gain).\n<\/li>\n<li>\nA net loss from Lumoxiti discontinued operations of \u20ac0.1m in 2022 (2021: net loss of \u20ac7.3m, -98.2%). This decrease mainly resulted from the Settlement Amount of $6.2m (\u20ac5.5m as of December 31, 2021) paid to AstraZeneca in April 2022 for an amount of \u20ac5.9m under the Termination and Transition agreement.\n<\/li>\n<li>\nA net loss of \u20ac58.1m in 2022 (2021: net loss of \u20ac52.8m).\n<\/li>\n<\/ul>\n<p>\nThe table below summarizes the IFRS consolidated financial statements as of and for the year ended December 31, 2022, including 2021 comparative information.\n<\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl bwwidth100\">\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwrowaltcolor0 bwwidth62\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>In thousands of euros, except for data per share<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrowaltcolor0 bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwrowaltcolor0 bwwidth18 bwalignr\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignr\">\n<b>December 31, 2022<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrowaltcolor0 bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwrowaltcolor0 bwwidth18 bwalignr\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignr\">\n<b>December 31, 2021<\/b>\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwpadl4 bwwidth62\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Revenue and other income<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwwidth18\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>57,674<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwwidth18\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>24,703<\/b>\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl4 bwwidth62\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nResearch and development\n<\/p>\n<\/td>\n<td class=\"bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth18\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(51,663)\n<\/p>\n<\/td>\n<td class=\"bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth18\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(47,004)\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwpadl4 bwwidth62\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nSelling, general and administrative\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwpadl0 bwsinglebottom bwpadr0 bwvertalignb bwwidth18\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(22,436)\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwpadl0 bwsinglebottom bwpadr0 bwvertalignb bwwidth18\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(25,524)\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwpadl4 bwwidth62\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Total operating expenses<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwpadl0 bwsinglebottom bwpadr0 bwvertalignb bwwidth18\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>(74,099)<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwpadl0 bwsinglebottom bwpadr0 bwvertalignb bwwidth18\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>(72,528)<\/b>\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwpadl4 bwwidth62\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Operating income (loss) before impairment<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwwidth18\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>(16,425)<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwwidth18\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>(47,825)<\/b>\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwpadl4 bwwidth62\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nImpairment of intangible asset\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwwidth18\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(41,000)\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwwidth18\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u2014\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwpadl4 bwwidth62\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Operating income (loss) after impairment<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwwidth18\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>(57,425)<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwwidth18\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>(47,825)<\/b>\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl4 bwwidth62\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nNet financial income (loss)\n<\/p>\n<\/td>\n<td class=\"bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth18\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(546)\n<\/p>\n<\/td>\n<td class=\"bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth18\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n2,347\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwpadl4 bwwidth62\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nIncome tax expense\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwwidth18\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u2014\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwwidth18\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u2014\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwpadl4 bwwidth62\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Net income (loss) from continuing operations<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwwidth18\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>(57,972)<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwwidth18\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>(45,478)<\/b>\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwpadl4 bwwidth62\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Net income (loss) from discontinued operations<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwwidth18\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>(131)<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwwidth18\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>(7,331)<\/b>\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwpadl4 bwwidth62\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Net income (loss)<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwwidth18\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>(58,103)<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwwidth18\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>(52,809)<\/b>\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl4 bwwidth62\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nWeighted average number of shares outstanding (in thousands)\n<\/p>\n<\/td>\n<td class=\"bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth18\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n79,640\n<\/p>\n<\/td>\n<td class=\"bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth18\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n79,543\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl4 bwwidth62\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nBasic income (loss) per share\n<\/p>\n<\/td>\n<td class=\"bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth18\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(0.73)\n<\/p>\n<\/td>\n<td class=\"bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth18\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(0.66)\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl4 bwwidth62\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nDiluted income (loss) per share\n<\/p>\n<\/td>\n<td class=\"bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth18\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(0.73)\n<\/p>\n<\/td>\n<td class=\"bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth18\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(0.66)\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl4 bwwidth62\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<i>Basic income (loss) per share from continuing operations<\/i>\n<\/p>\n<\/td>\n<td class=\"bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth18\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<i>(0.73)<\/i>\n<\/p>\n<\/td>\n<td class=\"bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth18\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<i>(0.57)<\/i>\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl4 bwwidth62\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<i>Diluted income (loss) per share from continuing operations<\/i>\n<\/p>\n<\/td>\n<td class=\"bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth18\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<i>(0.73)<\/i>\n<\/p>\n<\/td>\n<td class=\"bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth18\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<i>(0.57)<\/i>\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl4 bwwidth62\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<i>Basic income (loss) per share from discontinued operations<\/i>\n<\/p>\n<\/td>\n<td class=\"bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth18\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<i>\u2014<\/i>\n<\/p>\n<\/td>\n<td class=\"bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth18\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<i>(0.09)<\/i>\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl4 bwwidth62\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<i>Diluted income (loss) per share from discontinued operations<\/i>\n<\/p>\n<\/td>\n<td class=\"bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth18\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<i>\u2014<\/i>\n<\/p>\n<\/td>\n<td class=\"bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth18\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<i>(0.09)<\/i>\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignb bwpadl0\" colspan=\"5\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignb bwpadl0 bwrowaltcolor0 bwwidth62\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwtablemarginb bwblockalignl bwrowaltcolor0 bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwrowaltcolor0 bwwidth18 bwalignr\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignr\">\n<b>December 31, 2022<\/b>\n<\/p>\n<\/td>\n<td class=\"bwtablemarginb bwblockalignl bwrowaltcolor0 bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwrowaltcolor0 bwwidth18 bwalignr\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignr\">\n<b>December 31, 2021<\/b>\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl4 bwwidth62\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nCash, cash equivalents and financial asset\n<\/p>\n<\/td>\n<td class=\"bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth18\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n136,604\n<\/p>\n<\/td>\n<td class=\"bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth18\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n159,714\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl4 bwwidth62\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nTotal assets\n<\/p>\n<\/td>\n<td class=\"bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth18\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n207,863\n<\/p>\n<\/td>\n<td class=\"bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth18\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n267,496\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl4 bwwidth62\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nShareholders\u2019 equity\n<\/p>\n<\/td>\n<td class=\"bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth18\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n54,151\n<\/p>\n<\/td>\n<td class=\"bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth18\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n107,440\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl4 bwwidth62\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nTotal financial debt\n<\/p>\n<\/td>\n<td class=\"bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth18\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n42,251\n<\/p>\n<\/td>\n<td class=\"bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth18\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n44,251\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<div class=\"bwpagebreakafter\">\n<\/div>\n<p>\n<b>About Innate Pharma:<\/b>\n<\/p>\n<p>\nInnate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through therapeutic antibodies and its ANKET<sup>\u00ae<\/sup> (<b>A<\/b>ntibody-based <b>NK<\/b> cell <b>E<\/b>ngager <b>T<\/b>herapeutics) proprietary platform.\n<\/p>\n<p>\nInnate\u2019s portfolio includes lead proprietary program lacutamab, developed in advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, monalizumab developed with AstraZeneca in non small cell lung cancer, as well as ANKET<sup>\u00ae<\/sup> multi-specific NK cell engagers to address multiple tumor types.\n<\/p>\n<p>\nInnate Pharma is a trusted partner to biopharmaceutical companies such as Sanofi and AstraZeneca, as well as leading research institutions, to accelerate innovation, research and development for the benefit of patients.\n<\/p>\n<p>\nHeadquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.\n<\/p>\n<p>\nLearn more about Innate Pharma at <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.innate-pharma.com&amp;esheet=53366651&amp;newsitemid=20230322005782&amp;lan=en-US&amp;anchor=www.innate-pharma.com&amp;index=4&amp;md5=32b475401e470c156ed935e3f652e59a\" rel=\"nofollow noopener\" shape=\"rect\">www.innate-pharma.com<\/a> and follow us on <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2Finnatepharma&amp;esheet=53366651&amp;newsitemid=20230322005782&amp;lan=en-US&amp;anchor=Twitter&amp;index=5&amp;md5=9c9b1c4e349227e9026516e73589fbec\" rel=\"nofollow noopener\" shape=\"rect\">Twitter<\/a> and <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Finnate-pharma%2F&amp;esheet=53366651&amp;newsitemid=20230322005782&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=6&amp;md5=9120baa6ec5d32d939f37bb00276a75c\" rel=\"nofollow noopener\" shape=\"rect\">LinkedIn<\/a>.\n<\/p>\n<p>\n<b>Information about Innate Pharma shares:<\/b>\n<\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl\">\n<tr>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>ISIN code<\/b>\n<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nFR0010331421\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Ticker code<\/b>\n<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nEuronext: IPH Nasdaq: IPHA\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>LEI<\/b>\n<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n9695002Y8420ZB8HJE29\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p>\n<b>Disclaimer on forward-looking information and risk factors:<\/b>\n<\/p>\n<p>\nThis press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including \u201cbelieve,\u201d \u201cpotential,\u201d \u201cexpect\u201d and \u201cwill\u201d and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company\u2019s commercialization efforts, the Company\u2019s continued ability to raise capital to fund its development. For an additional discussion of risks and uncertainties which could cause the Company&#8217;s actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (\u201cFacteurs de Risque&#8221;) section of the Universal Registration Document filed with the French Financial Markets Authority (\u201cAMF\u201d), which is available on the AMF website <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.amf-france.org&amp;esheet=53366651&amp;newsitemid=20230322005782&amp;lan=en-US&amp;anchor=http%3A%2F%2Fwww.amf-france.org&amp;index=7&amp;md5=aa62f73da6558a9f8820c82fcb519d72\" rel=\"nofollow noopener\" shape=\"rect\">http:\/\/www.amf-france.org<\/a> or on Innate Pharma\u2019s website, and public filings and reports filed with the U.S. Securities and Exchange Commission (\u201cSEC\u201d), including the Company\u2019s Annual Report on Form 20-F for the year ended December 31, 2021, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public, by the Company.\n<\/p>\n<p>\nThis press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b><span class=\"bwuline\">Investors &amp; Media<\/span><\/b><br \/><b>Innate Pharma<\/b><br \/>Henry Wheeler<br \/>\n<br \/>Tel.: +33 (0)4 84 90 32 88<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#97;i&#x6c;&#x74;&#111;:&#x68;&#x65;&#110;r&#x79;&#46;w&#x68;&#x65;&#101;l&#x65;&#x72;&#64;i&#x6e;&#110;&#97;&#x74;&#x65;&#45;p&#x68;&#x61;&#114;m&#x61;&#46;&#102;r\" rel=\"nofollow noopener\" shape=\"rect\">h&#101;&#110;&#114;&#x79;&#x2e;&#x77;he&#101;&#108;&#x65;&#x72;&#x40;&#x69;nn&#97;&#116;&#x65;&#x2d;&#x70;&#x68;a&#114;&#109;&#97;&#x2e;&#x66;&#x72;<\/a>\n<\/p>\n<p>\n<b>Newcap<\/b><br \/>Arthur Rouill\u00e9<br \/>\n<br \/>Tel.: +33 (0)1 44 71 00 15<br \/>\n<br \/><a target=\"_blank\" href=\"m&#97;&#105;&#x6c;&#x74;o&#58;&#105;&#x6e;&#x6e;&#x61;t&#101;&#64;&#x6e;&#x65;wc&#97;&#x70;&#x2e;&#x65;u\" rel=\"nofollow noopener\" shape=\"rect\">&#x69;&#x6e;&#x6e;&#x61;&#116;&#101;&#64;ne&#x77;&#x63;&#x61;&#x70;&#46;&#101;u<\/a>\n<\/p>\n<p> <a href=\"http:\/\/www.businesswire.com\/news\/home\/20230322005782\/en\/Innate-Pharma-Reports-Full-Year-2022-1-Financial-Results-and-Business-Update\/?feedref=Zd8jjkgYuzBwDixoAdXmJgT1albrG1Eq4mAeVP392103_ypKzv-7ah0oHKWbnuHnevRMp3sIgu8q3wq1OF24lT93qbEzrwa15HGbLqMObxZM7XiMhduiSeKMTNDLRqI_doMC3CVAuyHo5cJ7XfDuvA==\"> Read full story here <\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Sanofi collaboration for Natural Killer cell engager therapeutics expanded to B7-H3 ANKET\u00ae program and two additional targets, with \u20ac25 million payment Encouraging preliminary TELLOMAK Phase 2 efficacy data for lacutamab in advanced cutaneous T cell lymphoma in S\u00e9zary syndrome and mycosis fungoides First patient dosed in monalizumab PACIFIC-9 Phase 3 lung cancer clinical trial with &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/innate-pharma-reports-full-year-20221-financial-results-and-business-update\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-55117","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Innate Pharma Reports Full Year 2022(1) Financial Results and Business Update - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/innate-pharma-reports-full-year-20221-financial-results-and-business-update\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Innate Pharma Reports Full Year 2022(1) Financial Results and Business Update - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Sanofi collaboration for Natural Killer cell engager therapeutics expanded to B7-H3 ANKET\u00ae program and two additional targets, with \u20ac25 million payment Encouraging preliminary TELLOMAK Phase 2 efficacy data for lacutamab in advanced cutaneous T cell lymphoma in S\u00e9zary syndrome and mycosis fungoides First patient dosed in monalizumab PACIFIC-9 Phase 3 lung cancer clinical trial with ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/innate-pharma-reports-full-year-20221-financial-results-and-business-update\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-23T06:03:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230322005782\/en\/1245155\/21\/INNATEvertnoirDS.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"16 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-reports-full-year-20221-financial-results-and-business-update\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-reports-full-year-20221-financial-results-and-business-update\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Innate Pharma Reports Full Year 2022(1) Financial Results and Business Update\",\"datePublished\":\"2023-03-23T06:03:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-reports-full-year-20221-financial-results-and-business-update\\\/\"},\"wordCount\":3310,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-reports-full-year-20221-financial-results-and-business-update\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230322005782\\\/en\\\/1245155\\\/21\\\/INNATEvertnoirDS.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-reports-full-year-20221-financial-results-and-business-update\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-reports-full-year-20221-financial-results-and-business-update\\\/\",\"name\":\"Innate Pharma Reports Full Year 2022(1) Financial Results and Business Update - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-reports-full-year-20221-financial-results-and-business-update\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-reports-full-year-20221-financial-results-and-business-update\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230322005782\\\/en\\\/1245155\\\/21\\\/INNATEvertnoirDS.jpg\",\"datePublished\":\"2023-03-23T06:03:18+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-reports-full-year-20221-financial-results-and-business-update\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-reports-full-year-20221-financial-results-and-business-update\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-reports-full-year-20221-financial-results-and-business-update\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230322005782\\\/en\\\/1245155\\\/21\\\/INNATEvertnoirDS.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230322005782\\\/en\\\/1245155\\\/21\\\/INNATEvertnoirDS.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-reports-full-year-20221-financial-results-and-business-update\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Innate Pharma Reports Full Year 2022(1) Financial Results and Business Update\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Innate Pharma Reports Full Year 2022(1) Financial Results and Business Update - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/innate-pharma-reports-full-year-20221-financial-results-and-business-update\/","og_locale":"en_US","og_type":"article","og_title":"Innate Pharma Reports Full Year 2022(1) Financial Results and Business Update - Pharma Trend","og_description":"Sanofi collaboration for Natural Killer cell engager therapeutics expanded to B7-H3 ANKET\u00ae program and two additional targets, with \u20ac25 million payment Encouraging preliminary TELLOMAK Phase 2 efficacy data for lacutamab in advanced cutaneous T cell lymphoma in S\u00e9zary syndrome and mycosis fungoides First patient dosed in monalizumab PACIFIC-9 Phase 3 lung cancer clinical trial with ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/innate-pharma-reports-full-year-20221-financial-results-and-business-update\/","og_site_name":"Pharma Trend","article_published_time":"2023-03-23T06:03:18+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230322005782\/en\/1245155\/21\/INNATEvertnoirDS.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"16 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/innate-pharma-reports-full-year-20221-financial-results-and-business-update\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/innate-pharma-reports-full-year-20221-financial-results-and-business-update\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Innate Pharma Reports Full Year 2022(1) Financial Results and Business Update","datePublished":"2023-03-23T06:03:18+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/innate-pharma-reports-full-year-20221-financial-results-and-business-update\/"},"wordCount":3310,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/innate-pharma-reports-full-year-20221-financial-results-and-business-update\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230322005782\/en\/1245155\/21\/INNATEvertnoirDS.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/innate-pharma-reports-full-year-20221-financial-results-and-business-update\/","url":"https:\/\/pharma-trend.com\/en\/innate-pharma-reports-full-year-20221-financial-results-and-business-update\/","name":"Innate Pharma Reports Full Year 2022(1) Financial Results and Business Update - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/innate-pharma-reports-full-year-20221-financial-results-and-business-update\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/innate-pharma-reports-full-year-20221-financial-results-and-business-update\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230322005782\/en\/1245155\/21\/INNATEvertnoirDS.jpg","datePublished":"2023-03-23T06:03:18+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/innate-pharma-reports-full-year-20221-financial-results-and-business-update\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/innate-pharma-reports-full-year-20221-financial-results-and-business-update\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/innate-pharma-reports-full-year-20221-financial-results-and-business-update\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230322005782\/en\/1245155\/21\/INNATEvertnoirDS.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230322005782\/en\/1245155\/21\/INNATEvertnoirDS.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/innate-pharma-reports-full-year-20221-financial-results-and-business-update\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Innate Pharma Reports Full Year 2022(1) Financial Results and Business Update"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55117","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=55117"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55117\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=55117"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=55117"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=55117"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}